PARP1 and Miyoshi myopathy: As CDK inhibitors such as dinaciclib have single agent efficacy in MM (144, 145) and are being studied actively as a therapeutic option, further mechanistic and pre-clinical studies of PARP inhibitors combined with other CDK inhibitors are warranted.